BMEA Stock Price
Biomea Fusion, Inc.
BMEA stock price is $1.42 (+3.67% on the day), giving Biomea Fusion, Inc. a market cap of $99.30M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
BMEA Stock Overview
- Price
- $1.42
- Previous close
- $1.37
- Open
- $1.38
- Market cap
- $99.30M
- P/E ratio
- -1.6
- 52-week range
- $0.87 - $2.99
- 1-year price target
- $7.00
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 26
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BMEA | $1.42 | +3.7% | 539.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |